DOCSLIB.ORG

C-Fos Expression Is a Molecular Predictor of Progression and Survival in Epithelial Ovarian Carcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
C-Fos Expression Is a Molecular Predictor of Progression and Survival in Epithelial Ovarian Carcinoma British Journal of Cancer (2008) 99, 1269 – 1275 & 2008 Cancer Research UK All rights reserved 0007 – 0920/08 $32.00 www.bjcancer.com C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma *,1,2 1,2 1,2 1 1 1 1 S Mahner , C Baasch , J Schwarz , S Hein ,LWo¨lber ,FJa¨nicke and K Milde-Langosch 1 Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany Members of the Fos protein family dimerise with Jun proteins to form the AP-1 transcription factor complex. They have a central function in proliferation and differentiation of normal tissue as well as in oncogenic transformation and tumour progression. We analysed the expression of c-Fos, FosB, Fra-1 and Fra-2 to investigate the function of Fos transcription factors in ovarian cancer. A total of 101 patients were included in the study. Expression of Fos proteins was determined by western blot analysis, quantified by densitometry and verified by immunohistochemistry. Reduced c-Fos expression was independently associated with unfavourable progression-free survival (20.6, 31.6 and 51.2 months for patients with low, moderate and high c-Fos expression; P ¼ 0.003) as well as overall survival (23.8, 46.0 and 55.5 months for low, moderate and high c-Fos levels; P ¼ 0.003). No correlations were observed for FosB, Fra-1 and Fra-2. We conclude that loss of c-Fos expression is associated with tumour progression in ovarian carcinoma and that c-Fos may be a prognostic factor. These results are in contrast to the classic concept of c-Fos as an oncogene, but are supported by the recently discovered tumour-suppressing and proapoptotic function of c-Fos in various cancer types. British Journal of Cancer (2008) 99, 1269 – 1275. doi:10.1038/sj.bjc.6604650 www.bjcancer.com & 2008 Cancer Research UK Keywords: ovarian cancer; prognostic factors; c-Fos; AP-1; survival; progression Ovarian cancer accounts for the highest tumour-related mortality assessed for prognostic significance over the past decades, but among women with gynaecologic malignancies. The American none of them yielded conclusive and reproducible results (Omura Cancer Society estimates about 23 000 new cases of ovarian cancer et al, 1991; Hornung et al, 2004; Winter et al, 2007). each year in the United States and that 70% of the affected women Recent efforts to develop accurate predictors of clinical outcome will die from their disease (American-Cancer-Society, 2007). have mainly focused on assessment of global gene expression by Although aggressive surgical cytoreduction and platinum-based DNA microarrays. This technology provided information on combination chemotherapy have improved outcome for many differential gene expression in a number of tumours including patients, long-term survival could not generally be improved. ovarian cancer (Hartmann et al, 2005) and has identified gene Identification of additional prognostic factors could help to stratify profiles associated with early relapse and decreased survival patients into different biological subgroups. In ovarian cancer, this (Spentzos et al, 2004). Members of the Fos family (c-Fos, FosB, Molecular Diagnostics is especially important for the group of patients with early relapse Fra-1 (Fos-related antigen 1) and Fra-2) are often represented in (within 6 months after first-line treatment) that usually die within these profiles (Meinhold-Heerlein et al, 2005). They dimerise with 6–12 months (du Bois et al, 2003). These patients (approximately the gene products of c-Jun, JunB or JunD to form the transcription 25%) do not benefit from current treatment modalities while factor Activating Protein 1 (AP-1). AP-1 binds to the promoter suffering from the sometimes severe side effects of therapy. region of specific target genes, converting extracellular signals into Subsequent research could then focus on the establishment of changes of gene expression (Milde-Langosch, 2005). As a member more targeted and individual treatment strategies in this subgroup, of AP-1, c-Fos has been implicated mainly in signal transduction, as previously shown for Her2/neu expression and trastuzumab cell differentiation and proliferation (Shaulian and Karin, 2001). treatment in breast cancer (Pegram et al, 2000). Many studies focused on its oncogenic functions and found that Widely accepted prognostic factors in patients with epithelial c-Fos regulated genes important for tumorigenesis, causing the ovarian cancer are International Federation of Gynecology and downregulation of tumour-suppressor genes (Bakin and Curran, Obstetrics (FIGO) stage and residual tumour volume after primary 1999) and leading to invasive growth of cancer cells (Hu et al, surgical cytoreduction (Bristow et al, 2002; Tingulstad et al, 2003). 1994). Furthermore, c-Fos can induce a loss of cell polarity and Several other clinical and biological factors such as age, epithelial-mesenchymal transition, leading to invasive and meta- performance status, tumour histology and grade have been static growth in mammary epithelial cells (Fialka et al, 1996). In addition to these experimental results, several reports investigated the function of c-Fos expression in human tumour *Correspondence: Dr S Mahner; E-mail: [email protected] tissue. In osteosarcoma and endometrial carcinoma, c-Fos over- 2 These authors contributed equally to this study. expression was associated with high-grade lesions and adverse Received 30 May 2008; revised 13 August 2008; accepted 13 August outcome (Gamberi et al, 1998; Bamberger et al, 2001). In a 2008 comparative analysis between precancerous lesion of the c-Fos expression in ovarian carcinoma S Mahner et al 1270 cervix uteri and invasive cervical cancer, c-Fos expression was Table 1 Patient characteristics significantly lower in precancerous lesions (Prusty and Das, 2005). C-Fos has also been identified as independent predictor of No. of patients 101 decreased survival in breast cancer (Bland et al, 1995). However, some more recent studies have raised the idea that Age (years) Mean 59.2 c-Fos may also have tumour-suppressor activity and might have a Median 61 function in apoptosis (Teng, 2000). Overexpression of c-Fos was Range 21 –87 found to inhibit cell cycle progression, stimulated murine hepatocyte cell death and strongly suppressed tumour formation FIGO stage in vivo (Mikula et al, 2003). A functional involvement of c-Fos in I10 apoptosis has been shown by its regulatory involvement during II 8 remodelling and stress response in various tissues in mouse III 60 development (Jochum et al, 2001). IV 23 Besides c-Fos, FosB, Fra-1 and Fra-2 have also been shown to Grading have a function in progression of various tumour types: FosB is 16 downregulated in poorly differentiated mammary carcinomas 229 (Bamberger et al, 1999), whereas Fra-1 and, partly, Fra-2 358 overexpression leads to enhanced tumour cell motility and Not determined/unknown 8 invasion in breast cancer, colorectal cancer and mesothelioma (Milde-Langosch, 2005). Lymph node metastasis This study investigated the potential function of Fos transcrip- N0 31 tion factors in ovarian cancer and analysed the expression and N1 55 prognostic significance of c-Fos, FosB, Fra-1 and Fra-2 in patients NX 15 with invasive epithelial ovarian carcinoma. Residual tumour after surgery Microscopic 67 o0.5 cm 7 MATERIALS AND METHODS 0.5– 1 cm 10 1–2cm 2 Patients 42cm 6 Not determined/unknown 9 Patients with epithelial ovarian carcinoma who presented for primary surgery at the University Medical Center Hamburg- Histologic subtype Eppendorf between 1997 and 2006 were included in this study. Serous 74 Thus, a total of 101 patients were retrospectively analysed. Detailed Mucinous 6 patient characteristics are listed in Table 1. Clinicopathologic Endometrioid 5 Molecular Diagnostics factors were evaluated by reviewing medical charts and pathologic Clear cell 1 records. Tissue slides were reviewed for histological classification Undifferentiated 7 and clinical outcome was followed from the date of surgery to the Mixed differentiation 8 date of death or until the end of 2007. Two cases were lost to Platinum-based first-line chemotherapy follow-up right after surgery and were excluded from the survival Adjuvant 90 analysis. All patients gave written informed consent to access their Neoadjuvant 6 tissue and review their medical records according to our None/unknown 5 investigational review board and ethics committee guidelines. CA 125 before surgery (kU lÀ1) Tissue samples Mean 2178 Median 436 Fresh-frozen samples were obtained intraoperatively and immedi- Range 21 – 47 000 ately stored at À801C. The histological characteristics of each sample were assessed on cryo-cut and haematoxylin-eosin-stained Survival (months), n ¼ 99 Progression-free survival sections and the tissue was trimmed if necessary to obtain at least Mean 19.7 70% tumour cells in the sample used for protein extraction. Median 15.2 Range 0.4–98 Protein extraction Overall survival Samples of approximately 100 mg were cut from the tissue and Mean 24.4 pulverised using a micro-dismembrator (Braun-Melsungen, Mel- Median 20 sungen, Germany) for 2 Â 45 s at 200 r.p.m. Proteins were lysed in Range 0.4–98 ice-cold sample buffer (50 mM Tris pH 6.8, 1% sodium dodecyl À1 FIGO ¼ International Federation of Gynecology and Obstetrics; kU/l ¼ kilo Units per sulphate (SDS), 10% sucrose and 10 mlml protease inhibitor liter. cocktail (Sigma, Taufkirchen, Germany)), and protein concentra- tion was determined following the standard protocols and using bovine serum albumin protein standards as described previously proteins from the ovarian cancer cell lines Ovcar5 and Ovcar8 and (Bamberger et al, 1999; Milde-Langosch et al, 2005). the breast cancer cell line MCF7 were loaded on each gel. After electrophoresis, blotting to polyvinylidene difluoride membranes 1 Western blot analysis and overnight incubation at 4 C in blocking solution, membranes were incubated for 1 h at room temperature with the following Equal amounts of protein (20 mg) of each sample were loaded per primary antibodies (all from Santa Cruz): c-Fos polyclonal well, and equal loading was verified by immunoblotting with actin antibody no.
Load more

Recommended publications
  • RNA-Binding Protein Hnrnpll Regulates Mrna Splicing and Stability During B-Cell to Plasma-Cell Differentiation
    RNA-binding protein hnRNPLL regulates mRNA splicing and stability during B-cell to plasma-cell differentiation Xing Changa,b, Bin Lic, and Anjana Raoa,b,d,e,1 Divisions of aSignaling and Gene Expression and cVaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; bSanford Consortium for Regenerative Medicine, La Jolla, CA 92037; and dDepartment of Pharmacology and eMoores Cancer Center, University of California at San Diego, La Jolla, CA 92093 Contributed by Anjana Rao, December 2, 2014 (sent for review July 20, 2014) Posttranscriptional regulation is a major mechanism to rewire the RBP-binding sites, thus validating the specificity of RBP binding transcriptomes during differentiation. Heterogeneous nuclear to coprecipitating RNAs and mapping RBP-binding sites on the RNA-binding protein LL (hnRNPLL) is specifically induced in terminally validated RNAs at close to single-nucleotide resolution (8). differentiated lymphocytes, including effector T cells and plasma Heterogeneous nuclear RNA-binding proteins (hnRNPs) is cells. To study the molecular functions of hnRNPLL at a genome- the term applied to a collection of unrelated nuclear RBPs. wide level, we identified hnRNPLL RNA targets and binding sites in hnRNPLL was identified through a targeted lentiviral shRNA plasma cells through integrated Photoactivatable-Ribonucleoside- screen for regulators of CD45RA to CD45RO switching during Enhanced Cross-Linking and Immunoprecipitation (PAR-CLIP) and memory T-cell development (9) and independently through RNA sequencing. hnRNPLL preferentially recognizes CA dinucleo- two separate screens performed by different groups for exclusion tide-containing sequences in introns and 3′ untranslated regions of CD45 exon 4 in a minigene context (10) and for altered CD44 (UTRs), promotes exon inclusion or exclusion in a context-dependent and CD45R expression on T cells in N-ethyl-N-nitrosourea manner, and stabilizes mRNA when associated with 3′ UTRs.
    [Show full text]
  • TGF-Β1 Signaling Targets Metastasis-Associated Protein 1, a New Effector in Epithelial Cells
    Oncogene (2011) 30, 2230–2241 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc ORIGINAL ARTICLE TGF-b1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells SB Pakala1, K Singh1,3, SDN Reddy1, K Ohshiro1, D-Q Li1, L Mishra2 and R Kumar1 1Department of Biochemistry and Molecular Biology and Institute of Coregulator Biology, The George Washington University Medical Center, Washington, DC, USA and 2Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA In spite of a large number of transforming growth factor b1 gene chromatin in response to upstream signals. The (TGF-b1)-regulated genes, the nature of its targets with TGF-b1-signaling is largely mediated by Smad proteins roles in transformation continues to be poorly understood. (Massague et al., 2005) where Smad2 and Smad3 are Here, we discovered that TGF-b1 stimulates transcription phosphorylated by TGF-b1-receptors and associate with of metastasis-associated protein 1 (MTA1), a dual master the common mediator Smad4, which translocates to the coregulator, in epithelial cells, and that MTA1 status is a nucleus to participate in the expression of TGF-b1-target determinant of TGF-b1-induced epithelial-to-mesenchymal genes (Deckers et al., 2006). Previous studies have shown transition (EMT) phenotypes. In addition, we found that that CUTL1, also known as CDP (CCAAT displacement MTA1/polymerase II/activator protein-1 (AP-1) co-activator protein), a target of TGF-b1, is needed for its short-term complex interacts with the FosB-gene chromatin and stimu- effects of TGF-b1 on cell motility involving Smad4- lates its transcription, and FosB in turn, utilizes FosB/histone dependent pathway (Michl et al.,2005).
    [Show full text]
  • Transcriptional Regulation by Extracellular Signals 209
    Cell, Vol. 80, 199-211, January 27, 1995, Copyright © 1995 by Cell Press Transcriptional Regulation Review by Extracellular Signals: Mechanisms and Specificity Caroline S. Hill and Richard Treisman Nuclear Translocation Transcription Laboratory In principle, regulated nuclear localization of transcription Imperial Cancer Research Fund factors can involve regulated activity of either nuclear lo- Lincoln's Inn Fields calization signals (NLSs) or cytoplasmic retention signals, London WC2A 3PX although no well-characterized case of the latter has yet England been reported. N LS activity, which is generally dependent on short regions of basic amino acids, can be regulated either by masking mechanisms or by phosphorylations Changes in cell behavior induced by extracellular signal- within the NLS itself (Hunter and Karin, 1992). For exam- ing molecules such as growth factors and cytokines re- ple, association with an inhibitory subunit masks the NLS quire execution of a complex program of transcriptional of NF-KB and its relatives (Figure 1; for review see Beg events. While the route followed by the intracellular signal and Baldwin, 1993), while an intramolecular mechanism from the cell membrane to its transcription factor targets may mask NLS activity in the heat shock regulatory factor can be traced in an increasing number of cases, how the HSF2 (Sheldon and Kingston, 1993). When transcription specificity of the transcriptional response of the cell to factor localization is dependent on regulated NLS activity, different stimuli is determined is much less clear. How- linkage to a constitutively acting NLS may be sufficient to ever, it is possible to understand at least in principle how render nuclear localization independent of signaling (Beg different stimuli can activate the same signal pathway yet et al., 1992).
    [Show full text]
  • Amplitude Modulation of Androgen Signaling by C-MYC
    Downloaded from genesdev.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Amplitude modulation of androgen signaling by c-MYC Min Ni,1,2 Yiwen Chen,3,4 Teng Fei,1,2 Dan Li,1,2 Elgene Lim,1,2 X. Shirley Liu,3,4,5 and Myles Brown1,2,5 1Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; 2Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA; 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; 4Harvard School of Public Health, Boston, Massachusetts 02215, USA Androgen-stimulated growth of the molecular apocrine breast cancer subtype is mediated by an androgen receptor (AR)-regulated transcriptional program. However, the molecular details of this AR-centered regulatory network and the roles of other transcription factors that cooperate with AR in the network remain elusive. Here we report a positive feed-forward loop that enhances breast cancer growth involving AR, AR coregulators, and downstream target genes. In the absence of an androgen signal, TCF7L2 interacts with FOXA1 at AR-binding sites and represses the basal expression of AR target genes, including MYC. Direct AR regulation of MYC cooperates with AR-mediated activation of HER2/HER3 signaling. HER2/HER3 signaling increases the transcriptional activity of MYC through phosphorylation of MAD1, leading to increased levels of MYC/MAX heterodimers. MYC in turn reinforces the transcriptional activation of androgen-responsive genes. These results reveal a novel regulatory network in molecular apocrine breast cancers regulated by androgen and AR in which MYC plays a central role as both a key target and a cooperating transcription factor to drive oncogenic growth.
    [Show full text]
  • Homeobox Gene Expression Profile in Human Hematopoietic Multipotent
    Leukemia (2003) 17, 1157–1163 & 2003 Nature Publishing Group All rights reserved 0887-6924/03 $25.00 www.nature.com/leu Homeobox gene expression profile in human hematopoietic multipotent stem cells and T-cell progenitors: implications for human T-cell development T Taghon1, K Thys1, M De Smedt1, F Weerkamp2, FJT Staal2, J Plum1 and G Leclercq1 1Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium; and 2Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands Class I homeobox (HOX) genes comprise a large family of implicated in this transformation proces.14 The HOX-C locus transcription factors that have been implicated in normal and has been primarily implicated in lymphomas.15 malignant hematopoiesis. However, data on their expression or function during T-cell development is limited. Using degener- Hematopoietic cells are derived from stem cells that reside in ated RT-PCR and Affymetrix microarray analysis, we analyzed fetal liver (FL) in the embryo and in the adult bone marrow the expression pattern of this gene family in human multipotent (ABM), which have the unique ability to self-renew and thereby stem cells from fetal liver (FL) and adult bone marrow (ABM), provide a life-long supply of blood cells. T lymphocytes are a and in T-cell progenitors from child thymus. We show that FL specific type of hematopoietic cells that play a major role in the and ABM stem cells are similar in terms of HOX gene immune system. They develop through a well-defined order of expression, but significant differences were observed between differentiation steps in the thymus.16 Several transcription these two cell types and child thymocytes.
    [Show full text]
  • KLF6 Depletion Promotes NF-Κb Signaling in Glioblastoma
    OPEN Oncogene (2017) 36, 3562–3575 www.nature.com/onc ORIGINAL ARTICLE KLF6 depletion promotes NF-κB signaling in glioblastoma AP Masilamani1,2, R Ferrarese1,2, E Kling1,2, NK Thudi3, H Kim4, DM Scholtens5, F Dai1,2, M Hadler1,2, T Unterkircher1,2, L Platania1,2, A Weyerbrock1,2, M Prinz6,7, GY Gillespie8, GR Harsh IV9, M Bredel3,10 and MS Carro1,2,10 Dysregulation of the NF-κB transcription factor occurs in many cancer types. Krüppel-like family of transcription factors (KLFs) regulate the expression of genes involved in cell proliferation, differentiation and survival. Here, we report a new mechanism of NF- κB activation in glioblastoma through depletion of the KLF6 tumor suppressor. We show that KLF6 transactivates multiple genes negatively controlling the NF-κB pathway and consequently reduces NF-κB nuclear localization and downregulates NF-κB targets. Reconstitution of KLF6 attenuates their malignant phenotype and induces neural-like differentiation and senescence, consistent with NF-κB pathway inhibition. KLF6 is heterozygously deleted in 74.5% of the analyzed glioblastomas and predicts unfavorable patient prognosis suggesting that haploinsufficiency is a clinically relevant means of evading KLF6-dependent regulation of NF-κB. Together, our study identifies a new mechanism by which KLF6 regulates NF-κB signaling, and how this mechanism is circumvented in glioblastoma through KLF6 loss. Oncogene (2017) 36, 3562–3575; doi:10.1038/onc.2016.507; published online 6 February 2017 INTRODUCTION coding region have been controversial.16,18–22 KLF6 has been The NF-κB transcription factor family is oncogenic through proposed to perform its tumor suppression function by promoting suppression of programmed cell death, and promotion of tumor G1 cell cycle arrest mainly through cyclin-dependent kinase 15 growth and invasion.1 In tumors, NF-κB can be activated by inhibitor 1A (CDKN1A) promoter transactivation.
    [Show full text]
  • KLF6-SV1 Overexpression Accelerates Human and Mouse Prostate Cancer Progression and Metastasis
    KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis Goutham Narla, … , Mark A. Rubin, John A. Martignetti J Clin Invest. 2008;118(8):2711-2721. https://doi.org/10.1172/JCI34780. Research Article Oncology Metastatic prostate cancer (PCa) is one of the leading causes of death from cancer in men. The molecular mechanisms underlying the transition from localized tumor to hormone-refractory metastatic PCa remain largely unknown, and their identification is key for predicting prognosis and targeted therapy. Here we demonstrated that increased expression of a splice variant of the Kruppel-like factor 6 (KLF6) tumor suppressor gene, known as KLF6-SV1, in tumors from men after prostatectomy predicted markedly poorer survival and disease recurrence profiles. Analysis of tumor samples revealed that KLF6-SV1 levels were specifically upregulated in hormone-refractory metastatic PCa. In 2 complementary mouse models of metastatic PCa, KLF6-SV1–overexpressing PCa cells were shown by in vivo and ex vivo bioluminescent imaging to metastasize more rapidly and to disseminate to lymph nodes, bone, and brain more often. Interestingly, while KLF6-SV1 overexpression increased metastasis, it did not affect localized tumor growth. KLF6-SV1 inhibition using RNAi induced spontaneous apoptosis in cultured PCa cell lines and suppressed tumor growth in mice. Together, these findings demonstrate that KLF6-SV1 expression levels in PCa tumors at the time of diagnosis can predict the metastatic behavior of the tumor; thus, KLF-SV1 may represent a novel therapeutic target. Find the latest version: https://jci.me/34780/pdf Research article KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis Goutham Narla,1,2 Analisa DiFeo,1 Yolanda Fernandez,1 Saravana Dhanasekaran,3 Fei Huang,1 Jaya Sangodkar,1,2 Eldad Hod,2 Devin Leake,4 Scott L.
    [Show full text]
  • Cross-Family Dimerization of Transcription Factors Fos/Jun
    Proc. Nati. Acad. Sci. USA Vol. 88, pp. 3720-3724, May 9, 1991 Biochemistry Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity (gene regulation/oncogenes/leucine zipper/protein dimerization/transcription) TSONWIN HAI*t AND ToM CURRANt of Medical Biochemistry and Ohio State Biotechnology Center, Ohio State University, 1060 Carmack Road, Columbus, OH 43210; and tDepartment*Department of Molecular Oncology and Virology, Roche Institute of Molecular Biology, Roche Research Center, Nutley, NJ 07110 Communicated by Herbert Weissbach, January 31, 1991 ABSTRACT The Fos/Jun and ATF/CREB families of Table 1. Mammalian Fos/Jun and ATF/CREB families transcription factors function in coupling extracellular signals Family Subfamily Gene(s) to alterations in expression of specific target genes. Like many eukaryotic transcription factors, these proteins bind to DNA as Fos/Jun Fos fos, fra-), fra-2, fosB dimers. Dimerization is mediated by a structure known as the Jun c-jun, junB, junD "leucine-zipper" motif. Although Fos/Jun and ATF/CREB ATF/CREB CREB CREB, ATF-I were previously thought to interact preferentially with differ- CRE-BP1 CRE-BPI, ATF-a ent DNA regulatory elements (the AP-1/TRE and ATF/CRE ATF-3 ATF-3* sites, respectively), we rind that members of these two families ATF-4 ATF4* form selective cross-family heterodimers. The resulting het- Alternative names for CRE-BPI are ATF-2 and HB16. ACREB is erodimers display distinguishable DNA binding speclfcities a spliced variant ofCREB, ATF-aA is a spliced variant ofATF-a, and from each other and from their parental homodimers.
    [Show full text]
  • Pax6 During Visual System Development
    Hedgehog-dependent E3-ligase Midline1 regulates ubiquitin-mediated proteasomal degradation of Pax6 during visual system development Thorsten Pfirrmanna,1, Enrico Jandta,1, Swantje Ranfta,b, Ashwin Lokapallya, Herbert Neuhausa, Muriel Perronc, and Thomas Hollemanna,2 aInstitute for Physiological Chemistry, University of Halle-Wittenberg, 06114 Halle, Germany; bGynecological Hospital, University Medical Center Mannheim, 68167 Mannheim, Germany; and cParis-Saclay Institute of Neuroscience, CNRS, Univ Paris Sud, Université Paris-Saclay, 91405 Orsay, France Edited by Richard M. Harland, University of California, Berkeley, CA, and approved July 19, 2016 (received for review January 16, 2016) Pax6 is a key transcription factor involved in eye, brain, and pancreas remains unclear how Pax6 protein is removed from the eyestalk development. Although pax6 is expressed in the whole prospective territory on time. Some authors report the regulation of Pax6 retinal field, subsequently its expression becomes restricted to the activity by posttranslational modifications (21–23), and most optic cup by reciprocal transcriptional repression of pax6 and pax2. interestingly, Tuoc et al. showed that in cortical progenitor cells, However, it remains unclear how Pax6 protein is removed from the Pax6 protein is degraded by the proteasome mediated by Trim11 eyestalk territory on time. Here, we report that Mid1, a member of (24). However, the existence of similar mechanisms leading to the RBCC/TRIM E3 ligase family, which was first identified in patients the development of the visual system is not known. with the X-chromosome–linked Opitz BBB/G (OS) syndrome, inter- The data of our present study show that Midline1 (Mid1) acts with Pax6. We found that the forming eyestalk is a major do- serves as one of these links.
    [Show full text]
  • Neurobiological Functions of the Period Circadian Clock 2 Gene, Per2
    Review Biomol Ther 26(4), 358-367 (2018) Neurobiological Functions of the Period Circadian Clock 2 Gene, Per2 Mikyung Kim, June Bryan de la Peña, Jae Hoon Cheong and Hee Jin Kim* Department of Pharmacy, Uimyung Research Institute for Neuroscience, Sahmyook University, Seoul 01795, Republic of Korea Abstract Most organisms have adapted to a circadian rhythm that follows a roughly 24-hour cycle, which is modulated by both internal (clock-related genes) and external (environment) factors. In such organisms, the central nervous system (CNS) is influenced by the circadian rhythm of individual cells. Furthermore, the period circadian clock 2 (Per2) gene is an important component of the circadian clock, which modulates the circadian rhythm. Per2 is mainly expressed in the suprachiasmatic nucleus (SCN) of the hypothalamus as well as other brain areas, including the midbrain and forebrain. This indicates that Per2 may affect various neurobiological activities such as sleeping, depression, and addiction. In this review, we focus on the neurobiological functions of Per2, which could help to better understand its roles in the CNS. Key Words: Circadian rhythm, Per2 gene, Sleep, Depression, Addiction, Neurotransmitter INTRODUCTION and lives in organisms because it can impart effects from the level of cells to organs including the brain. Thus, it is neces- A circadian rhythm is any physiological process that displays sary to understand clock-related genes that are controlling the a roughly 24 hour cycle in living beings, such as mammals, circadian rhythm endogenously. plants, fungi and cyanobacteria (Albrecht, 2012). In organ- The Period2 (Per2) gene is a member of the Period family isms, most biological functions such as sleeping and feeding of genes consisting of Per1, Per2, and Per3, and is mainly patterns are adapted to the circadian rhythm.
    [Show full text]
  • Fosb Induction in Nucleus Accumbens by Cocaine Is Regulated by E2f3a
    New Research Disorders of the Nervous System Fosb Induction in Nucleus Accumbens by Cocaine Is Regulated by E2F3a Hannah M. Cates,1 Casey K. Lardner,1 Rosemary C. Bagot,1 Rachael L. Neve,2 and Eric J. Nestler1 https://doi.org/10.1523/ENEURO.0325-18.2019 1Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029 and 2Gene Delivery Technology Core, Massachusetts General Hospital, Cambridge, Massachusetts 02139 Abstract The transcription factor ⌬FosB has been proposed as a molecular switch for the transition from casual, volitional drug use into a chronically addicted state, but the upstream regulatory mechanisms governing ⌬FosB expression are incompletely understood. In this study, we find a novel regulatory role for the transcription factor E2F3, recently implicated in transcriptional regulation by cocaine, in controlling ⌬FosB induction in the mouse nucleus accumbens (NAc) following cocaine administration. We find that an E2F consensus sequence 500 bp upstream of the Fosb transcription start site is enriched for E2F3 specifically over other E2F isoforms. We further conclude that ⌬FosB expression is regulated specifically by E2F3a, not E2F3b, that E2f3a expression is specific to D1 receptor-expressing medium spiny neurons, and that E2F3a overexpression in NAc recapitulates the induction of Fosb and ⌬Fosb mRNA expression observed after chronic cocaine exposure. E2F3a knockdown in NAc does not abolish ⌬Fosb induction by cocaine, a result consistent with previously published data showing that singular knockdown of upstream regulators of ⌬FosB is insufficient to block cocaine-induced expression. Finally, to elucidate potential combinatorial epigenetic mechanisms involved in E2F3a’s regulation of Fosb, we explore H3K4me3 enrichment at the Fosb promoter and find that it is not enhanced by E2F3a overexpression, suggesting that it may instead be a pre-existing permissive mark allowing for E2F3a to interact with Fosb.
    [Show full text]
  • BCL6 Repression of EP300 in Human Diffuse Large B Cell Lymphoma Cells Provides a Basis for Rational Combinatorial Therapy Leandro C
    Research article BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy Leandro C. Cerchietti,1,2 Katerina Hatzi,1,2 Eloisi Caldas-Lopes,3 Shao Ning Yang,1,2 Maria E. Figueroa,1,2 Ryan D. Morin,4 Martin Hirst,4 Lourdes Mendez,1 Rita Shaknovich,5 Philip A. Cole,6 Kapil Bhalla,7 Randy D. Gascoyne,8 Marco Marra,4 Gabriela Chiosis,3 and Ari Melnick1,2 1Hematology and Oncology Division, and 2Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. 3Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. 4Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 5Department of Pathology, Weill Cornell Medical College, New York, New York, USA. 6Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 7The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. 8Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada. B cell lymphoma 6 (BCL6), which encodes a transcriptional repressor, is a critical oncogene in diffuse large B cell lymphomas (DLBCLs). Although a retro-inverted BCL6 peptide inhibitor (RI-BPI) was recently shown to potently kill DLBCL cells, the underlying mechanisms remain unclear. Here, we show that RI-BPI induces a particular gene expression signature in human DLBCL cell lines that included genes associated with the actions of histone deacetylase (HDAC) and Hsp90 inhibitors.
    [Show full text]